A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer
- Authors:
- Published online on: January 1, 2006 https://doi.org/10.3892/or.15.1.123
- Pages: 123-127
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Advanced non-small cell lung cancer (NSCLC) remains a difficult cancer to treat, and evolution of platinum-free regimens in a first-line setting is ongoing. This was a dose-finding study on the docetaxel and vinorelbine combination. Docetaxel was given at 60 mg/m2 on day 1 only, and vinorelbine was given on days 1 and 15 starting at 20 mg/m2, then escalated to 30 and 40 mg/m2 in two dose cohorts. Each cycle lasted 28 days. The maximum tolerated dose was 60 mg/m2 docetaxel and 30 mg/m2 vinorelbine. Twenty-one patients were enrolled and showed an overall response rate of 9.5%, with stable disease documented in 33% of patients. The dosage schedule of this combination resulted in acceptable toxicities. The median time to progression was 5.86 months (95% CI 2.50-9.22), and median survival was 10.96 months (95% CI 1.42-20.51) with a 1-year survival rate of 50%. This combination may be important for patients with NSCLC.
